These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34231104)

  • 21. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
    Galis ZS; Sukhova GK; Lark MW; Libby P
    J Clin Invest; 1994 Dec; 94(6):2493-503. PubMed ID: 7989608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulated Sphingosine 1-Phosphate Receptor 1 Expression in Human and Murine Atherosclerotic Plaques.
    Liu H; Jin H; Han J; Yue X; Yang H; Zayed MA; Gropler RJ; Tu Z
    Mol Imaging Biol; 2018 Jun; 20(3):448-456. PubMed ID: 29134505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice.
    Laitinen I; Saraste A; Weidl E; Poethko T; Weber AW; Nekolla SG; Leppänen P; Ylä-Herttuala S; Hölzlwimmer G; Walch A; Esposito I; Wester HJ; Knuuti J; Schwaiger M
    Circ Cardiovasc Imaging; 2009 Jul; 2(4):331-8. PubMed ID: 19808614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: correlation with in vivo 17.6T MRI.
    Li X; Bauer W; Israel I; Kreissl MC; Weirather J; Richter D; Bauer E; Herold V; Jakob P; Buck A; Frantz S; Samnick S
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1661-7. PubMed ID: 24903095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging of hypoxia in mouse atherosclerotic plaques with (64)Cu-ATSM.
    Nie X; Randolph GJ; Elvington A; Bandara N; Zheleznyak A; Gropler RJ; Woodard PK; Lapi SE
    Nucl Med Biol; 2016 Sep; 43(9):534-542. PubMed ID: 27372286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation.
    Razavian M; Tavakoli S; Zhang J; Nie L; Dobrucki LW; Sinusas AJ; Azure M; Robinson S; Sadeghi MM
    J Nucl Med; 2011 Nov; 52(11):1795-802. PubMed ID: 21969358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers.
    Skjøt-Arkil H; Barascuk N; Register T; Karsdal MA
    Assay Drug Dev Technol; 2010 Oct; 8(5):542-52. PubMed ID: 20662734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis.
    Quillard T; Tesmenitsky Y; Croce K; Travers R; Shvartz E; Koskinas KC; Sukhova GK; Aikawa E; Aikawa M; Libby P
    Arterioscler Thromb Vasc Biol; 2011 Nov; 31(11):2464-72. PubMed ID: 21903941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deletion of Periostin Protects Against Atherosclerosis in Mice by Altering Inflammation and Extracellular Matrix Remodeling.
    Schwanekamp JA; Lorts A; Vagnozzi RJ; Vanhoutte D; Molkentin JD
    Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):60-8. PubMed ID: 26564821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques.
    Deguchi JO; Aikawa E; Libby P; Vachon JR; Inada M; Krane SM; Whittaker P; Aikawa M
    Circulation; 2005 Oct; 112(17):2708-15. PubMed ID: 16230484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of [
    Bala G; Baudhuin H; Remory I; Gillis K; Debie P; Krasniqi A; Lahoutte T; Raes G; Devoogdt N; Cosyns B; Hernot S
    Mol Imaging Biol; 2018 Apr; 20(2):260-267. PubMed ID: 28875290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (
    Varasteh Z; De Rose F; Mohanta S; Li Y; Zhang X; Miritsch B; Scafetta G; Yin C; Sager HB; Glasl S; Gorpas D; Habenicht AJR; Ntziachristos V; Weber WA; Bartolazzi A; Schwaiger M; D'Alessandria C
    Theranostics; 2021; 11(4):1864-1876. PubMed ID: 33408786
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging.
    Ouimet T; Lancelot E; Hyafil F; Rienzo M; Deux F; Lemaître M; Duquesnoy S; Garot J; Roques BP; Michel JB; Corot C; Ballet S
    Mol Pharm; 2012 Apr; 9(4):850-61. PubMed ID: 22352457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules.
    Müller A; Mu L; Meletta R; Beck K; Rancic Z; Drandarov K; Kaufmann PA; Ametamey SM; Schibli R; Borel N; Krämer SD
    Int J Cardiol; 2014 Jul; 174(3):503-15. PubMed ID: 24834996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular extracellular matrix in atherosclerosis.
    Chistiakov DA; Sobenin IA; Orekhov AN
    Cardiol Rev; 2013; 21(6):270-88. PubMed ID: 23422022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and preclinical evaluation of a novel fluorine-18 labeled small-molecule PET radiotracer for imaging of CXCR3 receptor in mouse models of atherosclerosis.
    Alluri SR; Higashi Y; Berendzen A; Grisanti LA; Watkinson LD; Singh K; Hoffman TJ; Carmack T; Devanny EA; Tanner M; Kil KE
    Res Sq; 2023 Feb; ():. PubMed ID: 36865232
    [No Abstract]   [Full Text] [Related]  

  • 37. Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis.
    Zhang X; Heo GS; Li A; Lahad D; Detering L; Tao J; Gao X; Zhang X; Luehmann H; Sultan D; Lou L; Venkatesan R; Li R; Zheng J; Amrute J; Lin CY; Kopecky BJ; Gropler RJ; Bredemeyer A; Lavine K; Liu Y
    J Nucl Med; 2024 May; 65(5):775-780. PubMed ID: 38548349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo.
    Deguchi JO; Aikawa M; Tung CH; Aikawa E; Kim DE; Ntziachristos V; Weissleder R; Libby P
    Circulation; 2006 Jul; 114(1):55-62. PubMed ID: 16801460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques.
    Hakimzadeh N; Pinas VA; Molenaar G; de Waard V; Lutgens E; van Eck-Smit BLF; de Bruin K; Piek JJ; Eersels JLH; Booij J; Verberne HJ; Windhorst AD
    PLoS One; 2017; 12(11):e0187767. PubMed ID: 29190653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.
    Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH
    Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.